OUR
COMPANY

LTS our CompanyLTS our Company

OUR
COMPANY

We enable our partners to succeed by doing what we do best

Since 1984 we have been focused on utilizing our expertise, experience and innovation to create market leading drug delivery solutions for our pharmaceutical partners.

Our three-point purpose

LTS Claim - WE CARE. WE CREATE. WE DELIVER.

Our three-point purpose

LTS Claim - WE CARE. WE CREATE. WE DELIVER.

Our three-point outcomes

CREATING
new therapeutic opportunities
MAXIMISING
partner value
IMPROVING
patient outcomes

LTS in numbers

1,500

employees

1,1 bn

systems produced

200

patent families owned

Our major milestones

2022

Acquisition of Tapemark Inc. in St. Paul, USA.

2019

The manufacturer’s authorisation for LTS is extended to the manufacturing of capsules.

2018

Launch of the first therapeutic equivalent generic version of Suboxone® sublingual film, in the United States by our partner Dr. Reddy’s. Buprenorphine and Naloxone Sublingual Film is a prescription medicine indicated for treatment of opioid use disorder.

2014

LTS manufactures the first OTF for the treatment of breakthrough pain in chronic cancer pain.

2013

Launch of an ondansetrone OTF for the treatment and prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy.

2012

Launch of the first ibuprofen patch, a local analgesic for the treatment of articular painful conditions, both traumatic and rheumatic.

2010

Launch of the first cutaneous patch with a high concentrate of capsaicin (8 %) indicated for the management of neuropathic pain associated with postherpetic neuralgia.

2007

Launch of the first transdermal patch for the treatment of Alzheimer’s disease.

2006

Launch of the first transdermal patch for the treatment of Parkinson’s disease.

1994

Foundation of LTS Corp. in West Caldwell, USA.

1990

The first nicotine patch for smoking cessation is launched in the US.

1984

The first TTS matrix system from LTS achieves approval and is launched, a nitroglycerin patch.